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57 ABSTRACT 
The present invention relates to the use of poly(Vinyl 
N-heterocycle)-block-poly(alkylene oxide) copolymers in 
micelle containing pharmaceutical formulations. The 
copolymers advantageously respond to pH differences in the 
environment to which they are exposed forming micelles at 
higher pH values. The micelles, which comprise a therapeu 
tic compound and a copolymer, deliver drug in a pH 
dependent manner. 
10 Claims, 3 Drawing Sheets 
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PH DEPENDENT POLYMER MICELLES 
The present application claims priority to Provisional 
Application U.S. Ser. No. 60/016,790, filed May 1, 1996. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to pH dependent polymer 
micelles used for the encapsulation of hydrophobic organic 
compounds. The invention relates more specifically to the 
encapsulation of hydrophobic drugs in micelles for use in 
drug delivery. 
2. Description of the Related Art 
Micelles have been prepared by a wide variety of methods 
using an equally diverse group of compounds. Polymers 
have been used to form micelles for drug delivery. Such 
micelle forming polymeric drug formulations have generally 
been designed to behave in a pH independent manner and 
have comprised nonionic polymers or copolymers. E. Arca 
et al., Int. J. Polymer Analysis & Characterization (1995), 2, 
pp. 31-41; C. Ropert et al., Biochem. Biophys. Res. Com 
mun. (1992), 187(2), pp. 379–885; K. Seki et al., Macro 
molecules (1984), 17, pp. 1692-1698; D. Collins and L. 
Huang in Molecular Mechanisms of Membrane Fusion (S. 
Ohki, D. Doyle, T. Flanagan, S. Hui and E. Mayhew, Eds; 
Plenum Press: N.Y. (1988), pp 149-161); D. Papahadjopou 
los and A. Gabizon in Horizons in Membrane Biotechnology 
(C. Nicolau and D. Chapman, Eds; Wiley-Liss: N.Y. (1990), 
pp. 85–93); and G. S. Kwon and K. Kazunori, Adv. Drug 
Delivery Reviews (1995), 16, 295-309. The prior art poly 
merS have generally been block copolymers. 
The primary drawbacks of those methods has been lack of 
Sufficient drug loading as well as lack of tissue targeting 
which is particularly important in the chemotherapeutic 
treatment of neoplasia related diseases Such as cancer and 
tumors. Additionally, prior art formulations have not been 
based on pH sensitive poly(Vinyl N-heterocycle) containing 
copolymers. 
Even though various methods have been developed to 
deliver hydrophobic drugs, no single method has been found 
to be universally applicable and have a high Success rate. 
Delivery of hydrophobic drugs resulting in increased bio 
availability and/or preferred tissue targeting remains a prob 
lem to the pharmaceutical industry. 
Accordingly, there is a need to develop more efficacious 
drug delivery methods for the delivery of hydrophobic 
drugs. Specifically, there is a need for formulations capable 
of forming Stable micelles under a first physiological 
condition, Such as high pH, and having the micelles dis 
rupted under a Second physiological conditions, Such as low 
pH. 
It is an object of the present invention to provide a 
formulation comprising the diblock copolymer poly(Vinyl 
N-heterocycle)-block-poly(alkylene oxide) and a pharmaco 
logically active compound, where the copolymer is capable 
of forming micelles in a pH dependent manner in an aqueous 
medium. 
It is another object of the present invention to provide a 
formulation comprising a pharmacologically active com 
pound and a poly(Vinyl N-heterocycle)-block-poly(alkylene 
oxide) copolymer which will form micelles in a water 
containing medium when the copolymer is in an environ 
ment having a pH where the N-heterocycle nitrogen(s) is 
unprotonated. 
It is yet another object of the present invention to provide 











pound and a poly(Vinyl N-heterocycle)-block-poly(alkylene 
oxide) copolymer which will form micelles when the 
N-heterocycle containing block is unprotonated and not 
form micelles when the N-heterocycle containing block is 
protonated. It is still yet another object of the present 
invention to provide a formulation comprising micelles 
which comprise a pharmacologically active compound and 
a poly(vinyl N-heterocycle)-block-poly(alkylene oxide) 
copolymer having pH dependent properties. Another object 
of the present invention to provide a micelle containing 
formulation wherein the micelle comprises a pharmacologi 
cally active compound and a poly(Vinyl N-heterocycle)- 
block-poly(alkylene oxide) copolymer that forms micelles at 
higher than physiological pH values and does not form 
micelles at lower than physiological pH values. 
It is a still further object of the present invention to 
provide a micelle containing pharmaceutical formulation, 
the micelle comprising a relatively hydrophobic therapeutic 
compound and a poly(Vinyl pyridine)-block-poly(ethylene 
oxide) copolymer having pH dependent properties. A further 
object of the present invention to provide a micelle contain 
ing pharmaceutical formulation having pH dependent 
properties, the micelle comprising a relatively hydrophobic 
therapeutic compound, a poly(Vinyl N-heterocycle) 
homopolymer and a poly(Vinyl N-heterocycle)-block-poly 
(alkylene oxide) copolymer. 
SUMMARY OF THE INVENTION 
The present invention is directed to micelle containing 
formulations that comprise a pharmacologically active com 
pound and a poly(Vinyl N-heterocycle)-block-poly(alkylene 
oxide) copolymer having pH dependent properties. The 
unique pH dependent formation of micelles characteristic of 
the present formulations make them particularly useful for 
controlled delivery of pharmacologically active agents, par 
ticularly therapeutic agents. 
Without intending to be limited to any particular mecha 
nism of action, the invention accomplishes the controlled 
release of pharmacologically active agents by providing a 
formulation containing micelles that include a pharmaco 
logically active agent which is released from the micelle as 
a function of pH. Generally Speaking, the micelles of the 
various formulations remain intact at higher pH values. 
Release of the pharmacologically active agent may be 
Selectively prevented Simply by manipulating the pH of the 
environment into which the formulation is introduced. Upon 
a relative decrease in pH (relative to the pH of the surround 
ing environment, for example tissue or fluid), the micellular 
formations in the preparation break down. 
The terms “high pH and “low” pH as used in the 
description of the present invention are relative terms. For 
example, a high pH value may be defined as a pH that is a 
value greater or about equal to the pKa of the nitrogens that 
comprise the poly(vinyl N-heterocycle) of the polymer of 
the micelle containing formulation. A low pH value as used 
in the definition of the invention is a pH that is below or less 
than the pKa of the nitrogens that comprise the poly(Vinyl 
N-heterocycle) of the polymer of the micelle containing 
formulation. 
The formulations of the invention are intended to include 
any formulation wherein about 5% to about 10% by volume 
of the formulation comprises the pH dependent micelles as 
described herein. However, formulations that include 20%, 
30%, 40%, 50%, 60%, 70%, 80%, 90% or even about 95% 
by Volume polymeric micelles are also contemplated by the 
present invention. Both water soluble and non-water soluble 
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pharmacologically active agents may be employed in the 
invention. By way of example and not limitation, it is 
anticipated that the invention will be useful in the delivery 
of anti-cancer drugs to target tissues, Such anti-cancer drugs 
that are well-known to those of skill in the art. Such 
anti-cancer agents are described in Goodman and Gilman's, 
The Pharmacological Basis of Therapeutics (18th ed.) 
(1990), which reference is specifically incorporated herein 
by reference. 
More Specifically, while again not intending to be limited 
to any mechanism or theory of action, the pH dependent 
behavior of micelle formation is dictated by the basicity of 
the N-heterocycle nitrogen(s) of the polymers that make up 
the micelle. At lower pH values, the N-heterocycle will be 
protonated, thereby forming a very hydrophilic diblock 
copolymer. This hydrophilic diblock copolymer is soluble in 
water containing medium. At higher pH values, the 
N-heterocycle of the polymeric composition will be 
unprotonated, thereby forming an amphoteric diblock 
copolymer. This amphoteric diblock copolymer will aggre 
gate into micelles. The N-heterocyclic portion of the copoly 
mer forms the core of the micelle, while the alkylene oxide 
portion forms the shell of the micelle. When pH decreases 
Sufficiently to permit the existence of the protonated 
N-heterocycle, there will be a decrease in micelle content 
Volume in the formulation. AS pH increases, the unproto 
nated N-heterocycle species will exist, resulting in the 
aggregation of the polymer into the described micelles. The 
pKa of the polymer and the heterocycle will dictate the 
micelle formation in the presently described formulations. 
The pKa of the polymer and the pKa of the heterocycle may 
and frequently will differ. 
It is contemplated that the present invention provides 
pharmaceutical formulations that are Suitable for adminis 
tration in any of a variety of methods known to the skilled 
artisan, Such as by oral, intravenous or intraperotineal 
administration. It is also contemplated and within the Scope 
of the present invention that the pharmaceutical formulation 
may contain more than one therapeutic compound. It is 
further contemplated and within the Scope of the present 
invention that the pharmaceutical formulation may be used 
in either a rapid or Sustained release dosage form. 
The Scope of the present invention also provides pharma 
ceutical formulations that may be used for the targeted 
delivery of therapeutic compounds to Specific biological 
tissues. 
In one embodiment of the invention, the micelle contain 
ing formulation comprises a pharmacologically active thera 
peutic compound, and a poly(Vinyl N-heterocycle)-block 
poly(alkylene oxide) copolymer, where the ability of the 
copolymer to form micelles is pH dependent, So that 
micelles will form at higher pH values but not at lower pH 
values. By way of example, micelle formation may occur in 
Some embodiments of the formulation at a pH above about 
5 to about 10. Below a pH of about 5, some embodiments of 
the formulations of the invention would have a reduced 
volume of micelles. This is because at relatively lower pH, 
the micelles would disassemble, releasing the pharmaco 
logically active agent included therein. 
In another embodiment, the present invention provides a 
micelle-containing pharmaceutical formulation that is 
capable of maintaining micellular form at a pH characteristic 
of the blood stream (pH about 6.75). In some of the 
formulations, the micelles are designed to dissipate in an 
environment of a lower pH, Such as upon contact with or 











cancer, carcinoma or tumor. Cancer tissue is hypoxic. The 
pH of cancer tissue generally is relatively lower than blood. 
The pH of cancer cells varies widely, and has been recog 
nized as having a pH as low as about 4.5. The micelle 
formulations of the invention therefore provide a convenient 
technique for targeting a pharmaceutically active agent to a 
cancer or other relatively low pH tissue via a blood carrier. 
In another embodiment, the invention comprises a capsule 
that comprises a micelle-containing formulation within an 
enteric coating. These formulations are Suitable for oral 
administration and are expected to minimize premature 
gastric release of the pharmacologically active agent or 
therapeutic compound. 
In Some embodiments, the micelle containing formula 
tions comprise a therapeutic compound and a poly(Vinyl 
N-heterocycle)-block-poly(ethylene oxide) copolymer hav 
ing the pH dependent properties described above. 
In other embodiments of the invention, the micelle con 
taining formulations comprise a pharmaceutical preparation 
that comprises a therapeutic compound, a poly(Vinyl 
N-heterocycle) homopolymer and a poly(Vinyl 
N-heterocycle)-block-poly(ethylene oxide) copolymer hav 
ing pH dependent properties. In Some embodiments, the 
micelle containing pharmaceutical formulation comprises a 
hydrophobic drug, a poly(Vinylpyridine) homopolymer and 
a poly(Vinyl pyridine)-block-poly(ethylene oxide) copoly 
C. 
In another aspect of the invention, a process for the 
preparation of a micelle containing pharmaceutical formu 
lation is provided. In Some embodiments, the process com 
prises combining a pharmacologically active agent, particu 
larly a therapeutic compound, with a poly(Vinyl 
N-heterocycle)-block-poly(alkylene oxide) copolymer hav 
ing pH dependent properties capable of forming micelles at 
high pH relative to the pKa of the polymer. 
In another embodiment, the proceSS comprises contacting 
a therapeutic compound with a poly(Vinyl pyridine) 
homopolymer and a poly(Vinyl N-heterocycle)-block-poly 
(alkylene oxide) copolymer having pH dependent properties 
to form micelles. 
The copolymers used in the micelle containing pharma 
ceutical formulation of the present invention include copoly 
mers of the formula I 
R-CHCH(R)-CHCH(R)O-H Formula I 
and all its isomeric, chiral, pharmaceutically acceptable Salt, 
oligomeric, polymeric, diastereomeric and/or racemic 
forms, wherein: 
R is H or a polymerization initiator Selected from: 
cumyl, S-butyl, n-butyl, 1,1-diphenylethyl, 1-phenyl-1- 
naphthylethyl, 1-phenyl-1-phenanthrylethyl, 
1-anthracyl-phenylethyl, 2-phenylpropyl or diphe 
nylmethyl; 




where, for the Structures containing an R. Substituted 
nitrogen, R may be absent from the nitrogen and R 
may attach to the structure backbone by way of the 
nitrogen; 
R is H or C1-C5 alkyl; 
R is C1-C5 alkyl when R is attached to the copolymer 
backbone by an atom other than the nitrogen to which 
R is attached; 
R is H or C1-C5 alkyl attached to any carbon on R; 
m is independently Selected at each occurrence from 50 to 
500; and 
n is independently Selected at each occurrence from 50 to 
500; 
to provide a chemically stable compound. 
The homopolymers used in micelle containing pharma 
ceutical formulation of the present invention include copoly 
mers of the formula II 
R-CHCH(R)-H Formula II 
and all its isomeric, chiral, pharmaceutically acceptable Salt, 
oligomeric, polymeric, diastereomeric and/or racemic forms 
wherein: 
R is H or a polymerization initiator Selected from: 
cumyl, S-butyl, n-butyl, 1,1-diphenylethyl, 1-phenyl-1- 
naphthylethyl, 1-phenyl-1-phenanthrylethyl, 
1-anthracyl-1-phenylethyl or diphenylmethyl, 
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Rs Rs 
where, for the structures containing an R. Substituted 
nitrogen, R may be absent from the nitrogen and R 
may attach to the structure backbone by way of the 
nitrogen; 
R is C1-C5 alkyl when R is attached to the copolymer 
backbone by an atom other than the nitrogen to which 
R is attached; 
Rs is H or C1-C5 alkyl attached to any carbon on R; and 
m is independently Selected at each occurrence from 50 to 
500; 
to provide a chemically stable compound. 
It is understood that the Substituents included in R 
possess different basicities. Therefore, it is contemplated and 
within the Scope of the invention that the compounds of 
formula I and formula II may be utilized in a broad range of 
pH values and still exhibit the necessary pH dependent 
micelle forming behavior. 
It should be understood that the particular combinations 
of R and R will result in various compounds of the formula 
I, each possessing its particular combination of properties. 
AS a result, one particular combination of R and R may be 
best Suited for a first therapeutic compound while another 
combination of R and R may be best Suited for a Second 
therapeutic compound. Methods for the Selection of a par 
ticular therapeutic compound/formula I compound combi 
nation follow below. Methods for the selection of a particu 
lar therapeutic compound/formula I compound/formula II 
compound combination follow below. 
Other features, advantages and embodiments of the inven 
tion will be apparent to those skilled in the art from the 
following description, accompanying data and appended 
claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1. Acid-base titration curve and first derivative plot 
of PVP-PEO with O.1 M NaOH. 
FIG. 2. Plot of micelle hydrodynamic volume vs total 
initial polymer concentration at elevated pH and constant 
copolymer:homopolymer ratio of 1:1. 
FIG. 3. Plot of micelle hydrodynamic volume vs total 
polymer concentration using various copolymer:homopoly 
mer ratios as indicated in the inset; where equals 3.96, X 
equals 1.71, A equals 1.05, equals 0.534 and O equals 
O.O. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The use of the pH dependent poly(vinyl N-heterocycle)- 
block-poly(alkylene oxide) copolymers of formula I for the 
preparation of micelle containing pharmaceutical formula 
tions has distinct advantages over the prior art. The present 
formulations exhibit a pH dependent micelle formation 
unlike that of prior art polymers or copolymers. When in the 
blood Stream, the present formulations should retain their 
micellular structure until they are exposed to a lower pH 
environment; thus they can be used to target delivery of 
5,955,509 
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drugs to tissues having a pH lower than that of the blood. 
Provided they are formulated So as to avoid gastric exposure, 
the present formulations should retain their micellular struc 
ture throughout the intestinal tract even as they croSS the 
intestinal wall and enter the blood stream. 
AS used herein, the term “poly(alkylene oxide)” includes 
all oligomers and polymers which are comprised of repeat 
ing units of allylene oxide. The present invention includes 
all the isomeric, diastereomeric, chiral, racemic, oligomeric 
and polymeric forms of the poly(alkylene oxides) included 
in the compounds of formula I above. The poly(allylene 
oxides) used in the invention may possess a wide range of 
molecular weights. 
The poly(alkylene oxides) comprising the pH dependent 
diblock copolymers of the present formulation are available 
commercially or may be made by a variety of methods, Such 
as described below or disclosed in Poly(ethylene glycol) 
Chemistry: Biotechnical and Biomedical Applications (J. M. 
Harris, Ed., Plenum Press, N.Y.) the teachings of which are 
hereby incorporated by reference. 
The term “alkylene oxide” refers to alkyl compounds 
containing two to Seven carbons and having an epoxide or 
oxirane ring at one end. The alkylene oxides which may be 
used in the invention include, by way of example and 
without limitation, ethylene oxide, propylene oxide, buty 
lene oxide, 1,2-epoxypentane, 1,2-epoxyhexane and 1,2- 
epoxyheptane. 
As used herein, the term “poly(vinyl N-heterocycle)” 
includes all oligomers and polymers comprised of repeating 
units of vinyl N-heterocycles. The present invention 
includes all the isomeric, diastereomeric, chiral, racemic, 
oligomeric and polymeric and pharmaceutically acceptable 
salt forms of the poly(vinyl N-heterocycles) included in the 
compounds of formula I and formula II above. The poly 
(vinyl N-heterocycles) useful in the invention may possess 
a wide range of molecular weights. The molecular weight of 
the poly(Vinyl N-heterocycle) will affect the aggregation 
number of the micelles Such that increasing molecular 
weight will increase the aggregation number. 
The poly(Vinyl N-heterocycles) comprising the pH depen 
dent diblock copolymers of the present formulation are 
available commercially or may be made by a variety of 
methods, such as described below or disclosed in Hirao et 
al., Polymer (1986), 27, 309; Nakahama et al., Macromol. 
Chem. Macromol Symp. (1993), 67,223; Morishima et al., 
J. Poly. Sci. Polymer Chem. Ed. (1982), 20, 299; and 
Kamachi et al., Macromolecules (1972), 5, 161 all the 
teachings of which are hereby incorporated by reference. 
The term “vinyl N-heterocycle” refers to an ethylene 
group Singly Substituted with either a 5-membered aromatic 
heterocyclic ring containing one to two nitrogens or a 
6-membered aromatic heterocyclic ring containing one to 
three nitrogens. At least one of the nitrogens in the hetero 
cycle must be able to form an addition Salt with an organic 
or inorganic acid. The N-heterocycle may be unsubstituted 
or substituted with simple alkyl groups. The 5-membered 
N-heterocycle may be attached by any of its carbon or 
nitrogen atoms to the Vinyl group provided that the nitrogen 
in the ring retain its acid addition Salt forming behavior. The 
6-membered N-heterocycle may be attached by any of its 
carbon atoms to the vinyl group. The 5- or 6-membered 
heterocyclic groups which may be used include pyridine, 
pyridazine, pyrimidine, pyrazine, S-triazine, pyrrole, imida 
Zole and pyrazole. 
The ratio poly(vinyl N-heterocycle) block size:poly 











pH dependent properties desired for the final formulation. It 
should be understood that the present copolymers are 
diblock copolymers, therefore, they possess a 1:1 incorpo 
ration ratio for the respective blocks. When a poly(vinyl 
N-heterocycle) homopolymer is mixed with the copolymer, 
the ratio of total poly(vinyl N-heterocycle) to total poly 
(alkylene oxide) exceed 1:1. 
The pH dependent copolymers of formula I may be 
prepared by a number of means as described in the examples 
below. Without limitation and by way of example, the 
general method for preparation of the copolymers follows 
the Scheme below for preparation of a poly(Vinyl pyridine)- 











- Y- R 
K 2) MeOH 
(~ Rs - 
N 
N R3 
It should be understood that the polymerization initiator, 
which caps one end of the poly(Vinyl pyridine) block may be 
any equivalent compound used for initiating polymeriza 
tions. Such equivalent compounds include, for example, 
S-butyl lithium, n-butyl lithium, cumyl potassium, 1,1- 
diphenyl-3-methylpentyl lithium, diphenylmethyl lithium, 
phenyl methide lithium, alkoxides and the like. Alkali based 
metals. Such as cesium, Sodium, lithium and potassium can 
be used to generate the initiators. If needed, the named 
initiators may be mixed with compounds Such as 1-aryl-1- 
phenylethylene, where aryl is naphthyl, phenanthryl, 
anthracyl, or the like. It should be understood that chelating 
compounds other than 18-crown-6 may be used. Such other 
chelating agents are disclosed in Topics in Weber et al., 
Current Chemistry (1981), 98, 1-35 the teachings of which 
are hereby incorporated by reference. 
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The pH dependent homopolymers of formula II may be 
prepared according to the first few steps of the above Scheme 
by quenching the polymerized poly(Vinyl N-heterocycle) 
with a hydrogen Source rather than reacting it with an 
alkylene oxide. 
The molecular weight of the poly(vinyl N-heterocycle) is 
controlled by varying the ratio concentration of monomer 
:concentration of initiator. Such methods of control are 
taught in M. Morton, Anionic Polymerizations: Principles 
and Practice (Academic Press, N.Y., 1983). 
An example of the pH dependent micelle formation 
behavior possessed by the formulation of the invention is 
shown in FIG. 1 where a poly(vinylpyridine)-block-poly 
(ethylene oxide) (PVP-PEO) copolymer is titrated with 
aqueous Sodium hydroxide. Titrating an initially acidic 
solution containing PVP-PEO with base, micelle formation 
begins at a pH that approximates the pKa of the PVP 
nitrogens. 
It should be understood that the pKa of the nitrogen(s) in 
the poly(vinyl N-heterocycle) block may be different than 
that for the respective vinyl N-heterocycle monomer. The 
pKa of the poly(vinyl N-heterocycle) block should be deter 
mined prior to use in a micelle containing formulation. An 
exemplary method for determining the pKa is detailed 
below. 
The micelles containing a therapeutic compound and a pH 
dependent poly(Vinyl N-heterocycle)-block-poly(alkylene 
oxide) copolymer of formula I may be prepared by a number 
of means as described in the examples below. The two 
general methods are “titration” and “direct dissolution'. The 
N-heterocyclic groups of the micelles need not be com 
pletely protonated in order to disrupt the micellular struc 
ture. 
When preparing micelles by the titration method below, 
the final micelle Size does not generally vary significantly 
with the rate of basification. The micelle size may depend 
upon the amount of poly(Vinyl N-heterocycle) homopoly 
mer mixed with the copolymer. FIG. 2 shows the effect 
initial total polymer concentration has upon the micelle 
hydrodynamic volume when the P2VP-PEO/P2VP ratio 
is held constant at 1:1 and a pH of 9 to 11 is used. FIG. 3 
shows the combined effect that varying the copolymer:ho 
mopolymer ratio and the total polymer concentration has 
upon the micelle hydrodynamic Volume size. Micelle Size 
may also be increased by letting the micelles form at a pH 
that approximates the pKa of the N-heterocycle nitrogen. 
Loading of the micelles with therapeutic compounds may 
be accomplished following the techniques below for the 
loading of hydrophobic compounds. Therapeutic compound 
loading into the micelles may be facilitated by also loading 
some poly(vinyl N-heterocycle) homopolymer into the 
micelles. It should be understood that the amount of com 
pound loading into the micelle will vary according to, for 
example, homopolymer: copolymer ratio therapeutic com 
pound:copolymer ratio in Solution used to prepare the 
micelle, N-heterocycle structure, individual block size of the 
diblock copolymer and Ltherapeutic compound structure. 
Although a given loading method may be optimal for a 
particular hydrophobic compound-copolymer combination, 
all of the described methods will generally result in com 
pound loading to Some degree. 
During Synthetic manipulation, the Vinyl N-heterocycles 
may possess protecting groups attached to their nitrogens. 
The various protecting groups contemplated for the Syn 
thetic procedures herein are disclosed in “Protective Groups 
in Organic Synthesis” (T. W. Greene; John Wiley and Sons, 











Synthesis, Biology”, Vol. 3 (Academic Press, New York, 
N.Y. 1981) the disclosures of which are hereby incorporated 
by reference. 
The therapeutic compounds loaded into the micelles of 
the invention may be used for treating indications Such as, 
by way of example and without limitation, inflammation, 
gout, hypercholesterolemia, microbial infection, AIDS, 
tuberculosis, fungal infection, cancer, tumor, organ 
rejection, diabetes, heart failure, arthritis, asthma, urinary 
tract infections, vaginal infections, Seizure related disorders, 
depression, psychosis, hypertension and birth control. 
The hydrophobic therapeutic compounds contemplated 
within the Scope of the invention include, by way of example 
and without limitation, Sulindac, colchicine, clofibrate, 
probucol, Sulfin pyraZone, methicillin, tetracycline, 
chloramphenicol, rifampin, griseofulvin, etoposide, 
daunorubicin, doxorubicin, cyclosporin, loSOXanthrone, 
tolbutamide and other structurally related compounds. The 
hydrophobic compounds may contain aromatic, peptide, 
hydrocarbon or other Such functional groups which gener 
ally render compounds hydrophobic. The hydrophobic com 
pounds may possess water Solubility to Some degree espe 
cially when the water is mixed with organic Solvents. 
Due to the extremely diverse structures found within the 
broad class of hydrophobic therapeutic compounds, it is 
likely that particular optimal therapeutic compound/poly 
(vinyl N-heterocycle)-block-poly(alkylene oxide) combina 
tions will need to be prepared. Such optimal combinations 
are easily determined and prepared using the methods 
detailed below. 
The following abbreviations may be used herein and are 
defined as follows: 
A-PVP anthracene labelled poly(2-vinlypyridine) homopolymer; 
DPA 9,10-diphenylanthracene; 
EO ethylene oxide; 
GPC gel permeation chromatography; 
MW molecular weight; 
Pdgels polydispersity as measured by QELS: 
PVP-PEO poly(vinylpyridine)-block-poly(ethylene oxide) copolymer; 
P2VP-PEO poly(2-vinylpyridine)-block-poly(ethylene oxide) 
copolymer; 
OELS quasi-electric light scattering; and 
2VP 2-vinylpyridine. 
It will be appreciated that certain compounds of the 
present invention which are used as monomers contain an 
asymmetrically Substituted carbon atom, and may be iso 
lated in optically active or racemic forms. It is well known 
in the art how to prepare optically active forms, Such as by 
resolution of racemic forms or by Synthesis, from optically 
active Starting materials. Also, it is realized that cis and trans 
geometric isomers of the compounds of the present inven 
tion are described and may be isolated as a mixture of 
isomers or as separated isomeric forms. All chiral, 
diastereomeric, racemic forms and all geometric isomeric 
forms of a structure are intended, unless the Specific Stere 
ochemistry or isomer form is specifically indicated. 
When a bond to a Substituent is shown to cross the bond 
connecting two atoms in a ring, then Such Substituent may be 
bonded to any atom on the ring. When a substituent is listed 
without indicating the atom via which Such Substituent is 
bonded to the rest of the compound of a given formula, then 
Such Substituent may be bonded via any atom in Such 
Substituent. For example, when the Substituent is pyridine, 
unless Specified otherwise, the pyridine group may be 




Combinations of Substituents and/or variables are permis 
Sible only if Such combinations result in Stable compounds. 
By stable compound or stable Structure it is meant herein a 
compound that is Sufficiently robust to Survive isolation to a 
useful degree of purity from a reaction mixture, and formu 
lation into an efficacious therapeutic agent. 
The term “Substituted”, as used herein, means that any 
one or more hydrogens on the designated atom is replaced 
with a Selection from the indicated group, provided that the 
designated atom's normal valency is not exceeded, and that 
the Substitution results in a Stable compound. 
As used herein, “alkyl” is intended to include branched or 
Straight-chain Saturated aliphatic hydrocarbon groups hav 
ing the specified number of carbon atoms. “Halo' or 
"halogen', as used herein, refers to fluoro, chloro, bromo, 
and iodo; and “counterion' is used to represent a Small, 
negatively charged species Such as chloride, bromide, 
hydroxide, acetate, Sulfate, and the like. 
The pharmaceutical formulation of the present invention 
may be administered by a variety of methods. Such methods 
include, by way of example and without limitation: 
intraperitoneal, intra-articular, intra-arterial, intracardiac, 
intracavity, intracartilaginous, intradermal, intrathecal, 
intraocular, intraspinal, intrasynovial, intrathoracic, 
intratracheal, intrauterine, epidural, percutaneous, 
intravascular, intravenous, intracoronary, intramuscular or 
Subcutaneous injection; inhalation; or oral, nasal, buccal, 
rectal ophthalmic, otic, urethral, vaginal, or Sublingual dos 
age administration. Such methods of administration and 
others contemplated within the Scope of the present inven 
tion are known to the skilled artisan. 
In vivo stability of the present formulation may vary 
according to the physiological environment to which it is 
exposed and the Specific therapeutic, vinyl N-heterocycle 
and alkylene oxide compounds used. Therefore, the neces 
sity for or frequency of readministration may be different for 
various formulations. 
It is known that cancer, carcinoma and tumor cells have 
Somewhat porous vascularization and are able to incorporate 
into their cellular endoplasm, by endocytosis, nanometer 
sized micelles. It is also known, that the hypoxic nature of 
cancer and tumor cells, generally render the cellular endo 
plasm more acidic than the Surrounding physiological envi 
ronment. For these reasons, it is anticipated, the present 
formulation will be particularly well Suited for selected 
delivery of drugs to cancer, tumor or carcinoma containing 
tissues. 
The micelles used in the present invention may be for 
mulated in a variety of ways. Any ingredients used in the 
present formulation should not disrupt micellular structure 
to any great extent, So that at least a Significant portion of the 
micelles will be mintact prior to administration. For 
injection, the micelles may be formulated, for reconstitution 
with an appropriate Solution, as, for example and without 
limitation: freeze dried, rotary dried or Spray dried powders, 
amorphous powders, or granules, precipitates or particu 
lates. For injection, the micelles may also be formulated as 
Suspensions or liquids in the appropriate Solutions, Such as, 
by way of example and without limitation, water, aqueous 
Solvents, nonprotic Solvents, protic Solvents, hydrophilic 
Solvents, hydrophobic Solvents, polar Solvents, nonpolar 
Solvent and/or combinations thereof, optionally containing 
Stabilizers, pH modifiers, Surfactants, bioavailability modi 
fiers and/or combinations thereof. The only requirements are 
that the pH dependent nature of the micelle not be lost and 
that the micelles retain their integrity prior to administration. 











injection or implant preparation which may be formulated in 
Such a manner as to permit a Sustained release of the active 
ingredient. The formulation can be compressed into pellets 
or Small cylinders and implanted Subcutaneously or intra 
muscularly as depot injections or implants. Implants may 
employ inert materials Such as biodegradable polymers or 
Synthetic Silicones, for examples, Silastic, Silicone rubber 
manufactured by the Dow-Corning Corporation. 
For inhalation either nasally or orally, the micelles of the 
invention may be formulated as Sprays or aerosols contain 
ing the appropriate Solvents (such as water, acqueous, 
nonaqueous, polar, nonpolar, hydropic, hydrophilic and/or 
combinations thereof) and optionally other compounds 
(Stabilizers, perfumes, antimicrobial agents, antioxdants, pH 
modifiers, surfactants and/or bioavailability modifiers). A 
propellant Such as compressed air, nitrogen, carbon dioxide 
or hydrocarbon based low boiling Solvents (Such as butane, 
propane or others) would be used in an aerosol formulation. 
For nasal administration, the same type of formulations 
used for the inhalation administration may be used. In 
addition, pastes, ointments or creams containing the micelles 
of the invention may also be used. It is contemplated that 
bioavailability enhancerS Such as alcohols or other com 
pounds that enhance the penetration of the micelles into the 
nasal mucosa may be needed to prepare Suitable formula 
tions for nasal administration. 
For oral, buccal, and Sublingual administration, the 
micelles of the invention may be administered as either 
Solutions or Suspensions in the form of gelcaps, caplets, 
tablets, capsules or powders. For rectal administration, the 
compounds of the invention may be administered in the 
form of Suppositories, ointments, enemas, tablets and 
creams for release of compound in the intestines, Sigmoid 
flexure and/or rectum. It is contemplated that the micelles 
may be formulated as for example and without limitation: 
freeze dried, rotary dried or Spray dried powders; amorphous 
or crystalline powders, or granules, precipitates or particu 
lates. The Solids used may be either free-flowing or com 
pressed. The compounds may also be formulated as 
ointments, creams, gels, slurries, Suspensions or liquids in 
Solutions, Such as, by way of example and without 
limitation, water, aqueous Solvents, nonprotic Solvents, pro 
tic Solvents, hydrophilic Solvents, hydrophobic Solvents, 
polar Solvents, nonpolar Solvent, emolients and/or combi 
nations thereof, optionally containing Stabilizers, pH 
modifiers, Surfactants, perfumes, astringents, cosmetic 
foundations, pigments, dyes, bioavailability modifiers and/ 
or combinations thereof. 
In Solid unit dosage forms the compounds can be com 
bined with conventional carriers, for example, binders, Such 
as acacia, corn Starch or gelatin; disintegrating agents, Such 
as, corn Starch, guar gum, potato Starch or alginic acid; 
lubricants, Such as, Stearic acid or magnesium Stearate; and 
inert fillers, Such as lactose, Sucrose or corn Starch. These 
carriers should not disrupt a significant portion of the 
micelles. 
The term “unit dosage form' is used herein to mean a 
Single or multiple dose form containing a quantity of the 
micelle containing formulation, Said quantity being Such that 
one or more predetermined units are normally required for 
a single therapeutic administration. In the case of multiple 
dose forms, Such as liquids or Scored tablets, Said predeter 
mined unit will be one fraction Such as 5 ml (teaspoon) 
quantity of a liquid or a half or quarter of a Scored tablet, of 
the multiple dose form. 
The compounds of general Formula I may also be admin 
istered as liquid Suspensions or Solutions using a Sterile 
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liquid, Such as an oil, water, an alcohol, or mixtures thereof, 
with or without the addition of a pharmaceutically suitable 
Surfactants, Suspending agent, or emulsifying agent for oral 
or parenteral administration. 
For liquid preparations, the compounds of Formula I can 
be formulated Suitably with oils, for example, fixed oils, 
Such as peanut oil, Sesame oil, cottonSeed oil, corn oil and 
olive oil; fatty acids, Such as oleic acid, Stearic acid and 
isotearic acid; and fatty acid esters, Such as ethyl oleate, 
isopropyl myristate, fatty acid glycerides and acetylated 
fatty acid glycerides, with alcohols, Such as ethanol, 
isopropanol, hexadecyl alcohol, glycerol and propylene gly 
col; with glycerol ketals, Such as 2,2-dimethyl-1,3- 
dioxolane-4-methanol, with ethers, Such as poly 
(ethyleneglycol) 450, with petroleum hydrocarbons, Such as 
mineral oil and petrolatum; with water, or with mixtures 
thereof; with or without the addition of a pharmaceutically 
Suitable Surfactant, Suspending agent or emulsifying agent. 
The only requirements are that the pH dependent behavior of 
the micelles not be lost and that a significant portion of the 
micelles remain present prior to administration. 
Oils can also be employed in the preparation of formu 
lations of the Soft gelatin type and Suppositories. Water, 
Saline, aqueous dextrose and related Sugar Solutions, and 
glycerols, Such as polyehtyleneglycol, may be employed in 
the preparation of liquid formulations which may Suitably 
contain Suspending agents, Such as pectin, carbomers, 
methyl cellulose, hydroxypropyl cellulose or carboxymethyl 
cellulose, as well as buffers and preservatives. Soaps and 
Synthetic detergents may be employed as Surfactants and as 
vehicles for detergent compositions. Suitable Soaps include 
fatty acid alkali metal, ammonium, and triethanolamine 
Salts. Suitable detergents include cationic detergents, for 
example, dimethyl dialkyl ammonium halides, alkyl pyri 
dinium halides, and alkylamine acetates, anionic detergents, 
for example, alkyl, aryl and olefin Sulfonates, alkyl, olefin, 
ether and monoglyceride Sulfates, and SulfoSuccinates, non 
ionic detergents, for example, fatty amine oxides, fatty acid 
alkanolamides, and polyoxyethylenepolyoxypropylene 
copolymers, and amphoteric detergents, for example, alkyl 
B-aminopropionates and 2-alkylimidazoline quaternary arn 
moniurn Salts, and mixtures thereof. The only requirements 
are that the pH dependent behavior of the micelles not be 
lost and that a significant portion of the micelles remain 
present prior to administration. 
It is contemplated that either one or a combination of 
Short-acting, long-acting, Sustained release, controlled 
release, pulsated release or slow release dosage forms may 
be used in the present invention. The course and duration of 
administration of and the dosage requirements for the 
micelles of the present invention will vary according to the 
Subject being treated, the compound being administered, the 
formulation used, the method of administration used, the 
Severity and type of indication being treated, the coadmin 
istration of other drags and other factors. 
The therapeutic compounds contained within the micelles 
may be formulated as their pharmaceutically acceptable 
Salts. AS used herein, "pharmaceutically acceptable Salts' 
refer to derivatives of the disclosed compounds wherein the 
parent compound is modified by making acid or base Salts 
thereof. Examples of pharmaceutically acceptable Salts 
include, but are not limited to, mineral or organic acid Salts 
of basic residues Such as amines, alkali or organic Salts of 
acidic residues Such as carboxylic acids, and the like. The 
pharmaceutically acceptable Salts include the conventional 
non-toxic Salts or the quaternary ammonium Salts of the 











inorganic or organic acids. For example, Such conventional 
non-toxic Salts include those derived from inorganic acids 
Such as hydrochloric, hydrobromic, Sulfuric, Sulfonic, 
Sulfamic, phosphoric, nitric and the like; and the Salts 
prepared from organic acids Such as amino acids, acetic, 
propionic, Succinic, glycolic, Stearic, lactic, malic, tartaric, 
citric, ascorbic, pamoic, male ic, hydroxy maleic, 
phenylacetic, glutamic, benzoic, Salicylic, Sulfanilic, 
2-ace to Xybenzoic, fu maric, tolue n e Sulfonic, 
methaneSulfonic, ethane disulfonic, oxalic, isethionic, and 
the like. 
The pharmaceutically acceptable Salts of the present 
invention can be Synthesized from the parent compound 
which contains a basic or acidic moiety by conventional 
chemical methods. Generally, Such Salts can be prepared by 
reacting the free acid or base forms of these compounds with 
a predetermined amount of the appropriate base or acid in 
water or in an organic Solvent, or in a mixture of the two. 
Generally, nonaqueous media are preferred. Lists of Suitable 
salts are found in Remington's Pharmaceutical Sciences, 
17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 
1418, the disclosure of which is hereby incorporated by 
reference. 
The phrase “pharmaceutically acceptable' is employed 
herein to refer to those compounds, materials, compositions, 
and/or dosage forms which are, within the Scope of Sound 
medical judgment, Suitable for use in contact with the tissues 
of human beings and animals without excessive toxicity, 
irritation, allergic response, or other problem or 
complication, commenSurate with a reasonable benefit/risk 
ratio. 
In Some embodiments, the invention comprises a micelle 
containing pharmaceutical formulation that includes a thera 
peutic compound and a poly(Vinyl N-heterocycle)-block 
poly(alkylene oxide) copolymer, where the copolymer is 
selected from a compound of the formula I 
R-CHCH(R)-CHCH(R)O-H Formula I 
and all its isomeric, chiral, pharmaceutically acceptable Salt, 
oligomeric, polymeric, diastereomeric and/or racemic forms 
wherein: 
R is H or a polymerization initiator Selected from the 
group consisting of: 
cumyl, S-butyl, n-butyl, 1,1-diphenylethyl, 1-phenyl-1- 
naphthylethyl, 1-phenyl-1-phen-phenanthrylethyl, 
1-anthracyl-phenylethyl, 2-phenylpropyl or diphe 
nylmethyl; 
R is Selected from the group consisting of 
N NS NS 
al? YS i? R-A 
N4 4. Nes 
N N 
y SN 
Rs - d 
Ne-N ax 
Rais H or C1-C5 alkyl; 
Rs is H or C1-C5 alkyl attached to any carbon or R; 
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m is independently Selected at each occurrence from 50 to 
400; and 
n is independently Selected at each occurrence from 50 to 
400; 
provided the ability of the copolymer to form micelles is pH 
dependent and the resulting compound is Stable. 
In other embodiments, the invention comprises a micelle 
containing pharmaceutical formulation that includes a thera 
peutic compound, a poly(Vinyl N-heterocycle) homopoly 
mer and a poly(Vinyl N-heterocycle)-block-poly(alkylene 
oxide) copolymer, where the copolymer is selected from a 
compound of the formula I wherein: 




R is H or C1-C5 alkyl; 
Rs is H; 
m is independently Selected at each occurrence from 50 to 
300; and 
n is independently Selected at each occurrence from 50 to 
300; and 
where the homopolymer is Selected from a compound of the 
formula II and all its isomeric, chiral, pharmaceutically 
acceptable Salt, oligomeric, polymeric, diastereomeric and/ 
or racemic forms wherein: 
R is H or a polymerization initiator Selected from: 
cumyl, S-butyl, n-butyl, 1,1-diphenylethyl, 1-phenyl-1- 
naphthylethyl, 1-phenyl-1-phenanthrylethyl, 
1-anthracyl-phenylethyl or diphenylmethyl, 
R is Selected from the group consisting of 
-C-O-Cl 
R is H or C1-C5 alkyl; 
R is H or C1-C5 alkyl attached to any carbon on R; and 
m is independently Selected at each occurrence from 50 to 
3OO. 
In yet other embodiments, the micelle containing phar 
maceutical formulation comprises a therapeutic compound 
and a poly(Vinyl N-heterocycle)-block-poly(alkylene oxide) 
copolymer, where the copolymer is Selected from a com 












R is Selected from the group consisting of 
E) - 2N N 
R is H or C1-C5 alkyl. 
The micelle containing pharmaceutical formulation may 
also comprise a therapeutic compound and a poly(Vinyl 
N-heterocycle)-block-poly(ethylene oxide) copolymer, 
where the copolymer is Selected from a compound of the 
formula I wherein: 
R is pyridine, and 
R is H. 
Unless otherwise indicated, all chemicals were purchased 
from Aldrich Chemicals (Milwaukee, Wis.). 
EXAMPLE 1. 
Analytical Methods used to Characterize the 
Polymers and Copolymers 
The gel permeation chromatography (GPC) system con 
sisted of a Waters pump (Model 510) and four Waters 
Millipore uStyragel columns (10,10", 10,500 A, in order 
of flow) using UV-Vis absorption, fluorescence and refrac 
tive index detectors, sequentially. A Hewlett Packard Vectra 
486DX4-100 computer supplied with the HP 1050 Diode 
Array Detector was equipped with an A/D board used to 
Simultaneously record the analog output from the Waters 
Differential Refractometer R401 and the Perkin-Elmer LS-1 
Fluorescence Detector. THF was used for the mobile phase 
at a flow rate of 1.5 ml/min. Polystyrene standards 
(Scientific Polymer Products) were used for calibration. For 
most detectors used in GPC systems, the detector response 
is proportional to the weight of the polymer Sample 
(differential refractive index; light Scattering; absorbance or 
fluorescence of chromophores that vary proportionally with 
the degree of polymerization). The average molecular 
weight moments were calculated with this assumption of 
detector response. 
All NMR measurements were performed on a Bruker 
AC-250 Spectrometer (250 MHz). The spectra were refer 
enced to residual Solvent protons. A ratio of the area under 
the aromatic region and the t-butyl peak for the unhydro 
lyzed polymer Samples was compared to the ratio derived 
from the GPC data. This comparison was used to verify 
values obtained for mole and weight fractions of the indi 
vidual copolymer blockS. 
EXAMPLE 2 
Preparation of Initiators used to Prepare 
Poly(2-vinylpyridine)-block-poly(ethylene oxide) 
1-(1-Hydroxy-1-methylethyl)naphthalene. A 10 ml (65.8 
mmole) quantity of 1-acetonaphthone was dissolved in 150 
ml of diethyl ether in a 500 ml, two neck, round bottom flask 
equipped with a pressure equalizing dropping finnel and 
fitted with a rubber Septum and a protected reflux condenser. 
A 138 ml (98 mmole) quantity of 1.4 M methyllithium in 
ether (Aldrich) was transferred to the fiumel by use of a 
cannula and nitrogen pressure. This was slowly added to the 
Stirred ketone over a 20 minute period. A light green color 
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indicated an excess of methyllithium. This was refluxed for 
an additional hour and the reaction was carefully quenched 
with water. The ether layer was made acidic using HCl, 
neutralized with NaHCO, dried using MgSO, and filtered. 
After the Solvent was removed, the crude product was 
recrystallized from benzene, filtered and washed with cold 
pentane to yield white, fibrous crystals (>98%), m.p. 81-86 
C. 1H NMR (acetone-d6): (=9.01 (m, 1 H, aromatic), 7.95 
(m, 1 H, aromatic), 7.82 (d, J-10.6, 1 H, aromatic), 7.68 (d. 
J=10.3, 1 H, aromatic), 7.50 (m, 3 H, aromatic), 4.30 (s, 1 
H, -OH), 1.84 (s, 6 H, -CH3). 
1-(1-Methoxy-1-methylethyl)naphthalene. A 12 g (64.4 
mmole) quantity of the compound made above was dis 
solved in 300 ml of THF employing the above setup without 
the funnel. About 2 g of NaH was slowly added to the stirred 
Solution. An excess was added once the H evolution ceased 
Such that Solid NaH settled on the bottom of the flask. A8.1 
ml (130 mmole) quantity of methyliodide was added at once, 
and the mixture was Stirred at room temperature overnight. 
(Methyl tosylate works in place of CHI, but the excess is 
difficult to remove.) This mixture was then acidified, 
neutralized, and isolated as described above. The crude, oily 
product was put through an Al-O column, eluted with 
hexane to remove the starting material (>90% yield). 
"HNMR (acetone-d6): (=8.95 (m, 1 H, aromatic), 7.84 (m, 
2 H, aromatic), 7.44 (m, 4 H, aromatic), 2.95 (s, 3 H, 
–OCH3), 1.73 (s, 6 H, -CH3). MS (CI+): m/z=200 (M+), 
185 (M+ -CH3), 169 (M+ —OCH3). 
Naphthylisopropyl potassium. The just prepared ether was 
reacted just as its cumyl analog to form the initiator. Potas 
sium was cut under mineral oil and washed with hexane. It 
was placed in the reaction vessel and Sublimed under 
dynamic vacuum to form a mirror. The was distilled in and 
2 was added. A deep red-orange color appeared immediately. 
The Solution was stirred overnight at room temperature and 
filtered to remove the precipitated MeOK. It was transferred 
to a pressure equalizing dropping funnel and protected from 
light. A fraction of this was titrated with acetanilide to 
calculate the molarity. Another portion was terminated with 
degassed methanol for structural analysis. 1H NMR 
(acetone-d6): (=8.18 (m, 1 H, aromatic), 7.90 (m, 1 H, 
aromatic), 7.74 (m, 1 H, aromatic), 7.50 (m, 4H, aromatic), 
3.78 (m, 1 H, -CH), 1.38 (d. 6 H, CH3). MS (CI+): 
m/z=170 (M+), 155 (M+ -CH3), 140, 129 (M+ -CH 
(CH3)2). 
1,1-Diphenyl-3-methylpentolithium. 1,1-Diphenylethylene 
(DPE) (Aldrich) was purified by vacuum distillation from 
s-butyl lithium (b.p. 75° C. at 1x10-3 torr). When s-butyl 
lithium was added to impure DPE, a green color appears first 
which turns to red/orange upon further addition. The green 
color is due to the benzophenone impurity. The DPE distil 
late was stored at 5 C. under N2 away from light. The 
molarity of s-butyl lithium (ca. 1.3 M in cyclohexane) was 
determined by titration with 0.1 ml of 2,5-dimethoxybenzyl 
alcohol to a red end-point indicating the dianion of the 
alcohol. 1.0 mmoles of S-butyl lithium of known concen 
tration was added to a flame-treated ampule containing 25.0 
ml THF and 0.35 ml (2.0 mmole) purified DPE. It is often 
convenient to dilute S-butyl lithium as received by 10 or 20 
fold with cyclohexane So that larger, more accurate Volumes 
could be measured. Alternatively, exact amounts of DPE 
dissolved in THF and S-butyl lithium needed for the poly 
merization could be added directly to the polymerization 
reactor after the Solvent has been distilled in. Due to the 
reactivity of S-butyl lithium, it should not be added to THF 













Preparation of Poly(2-vinylpyridine)-block-poly 
(ethylene oxide): P2VP-PEO 
A 10:1 molar ratio of 18-crown-6 ether to cumyl potas 
sium was added to the reactor in order to activate the 
propagating Species. 18-crown-6 was added to the flame 
treated reactor and a dynamic vacuum was applied to degas 
and dry the ether. THF was distilled in and titrated. A larger 
than usual amount of the initiator was needed to titrate the 
reaction Solvent due to the remaining impurities in the 
18-crown-6.2VP was added dropwise to a solution of the 
activated initiator and allowed to react 30 minutes. An 
aliquot was withdrawn at this point and terminated with 
MeOH. After the addition of ethylene oxide, the reaction 
was allowed to proceed 40 to 48 hours. The P2VP anion 
color faded over a period of one half hour. The dry ice/ 
isopropyl alcohol bath remained in place but no additional 
dry ice was added over this period of time. This allowed the 
polymerization Solution to slowly rise to room temperature. 
This elevated temperature was necessary for EO to poly 
merize to high molecular weights. The polymerization reac 
tor was under pressure at 25 C. due to the increased vapor 
pressure of both the THF and EO (b.p.-10° C. at 1 atm.). 
However, some fraction of EO was constantly present in 
solution (Henry's Law) and able to be polymerized. The 
anion was terminated with 0.5 ml MeOH. The copolymer 
was recovered by precipitation in hexane and the aliquot was 
precipitated in H2O. 
The P2VP-PEO sample contained a significant amount of 
P2VP homopolymer. The homopolymer was removed by 
fractional precipitation. A 0.61 g quantity of P2VP-PEOs 
containing approximately 1:1 mole ratio of homopolymer to 
copolymer was dissolved in 13.0 ml of benzene at room 
temperature. A 3.3 ml quantity of isooctane was added 
dropwise. The precipitate (mostly homopolymer) was 
allowed to settle 24–48 hours. The Supernatant was carefully 
decanted and freeze-dried. There was evidence by GPC that 
a low molecular weight peak at about 5,000 g/mole appears 
if the Solution was not allowed to Settle or was not centri 
fuged adequately. This was due to lower molecular weight 
P2VP remaining suspended. This process of dissolving in 
benzene and precipitation was repeated until the GPC chro 
matogram for the copolymer was monomodal or unchanged. 
TABLE 1. 
SPC Results for Diblock Copolymer Synthesis 
Ra Fluor. ODf Targ. 
Polymer <MW> PD <MW> PD <MW> PD MW 
PVP 14,000 1.1 14,000 1.1 25K 
PVP-PEO 16,500 1.2 17,000 1.2 SOK 
PVP 25,000 1.O 25,000 1.O 3OK 
A-PVP 55,000 1.1 52,000 1.37 53,000 1.1 35K 
Differential refractive index detection. 
Number average molecular weight (g/mole) and polydispersity, PD = <M>w/ 
<M- 
Number average molecular weight (g/mole) and polydispersity, PD = <Mew? 
<Ms computed from a PS calibration curve and taking the RI signal to be 
R9peritoneal to the polymer weight, as is stand procedure 
Signifies an excess of fluorescent monomer which causes “tailing in 
chromatogram. 
Values include shoulder, maximum value = 28,000 g/mole. 




Physical Data for PVP Containing Copolymers 
For PVP block 
Polymer <MW> PD xd 2VP/EO 
PVP-PEO 14,000 1.18 O.53 O.48 
PP-PEOs 14,000 1.07 O.47 O.38 
Since the PVP blocks have similar molecular weights (DPs = 133 for both), 
each PVP-PEO copolymer is distinguished by the DP of the PEO block. 
Number average molecular weight for the PVP block by GPC. 
Monomer ratio in the copolymer (purified when necessary) by NMR. 
Weight fraction of PVP in copolymer. 
TABLE 3 
Data for Comparison of Micelle Preparation Methods 
pyrene' 
Method (PVP-PEO di. Is OD(325) (%) I/I 




Titration 0.46 51.7 28 O.O319 1.01 1.5 
(0.27) 
1.OO 48.9 62 O.116 3.66 1.4 
(0.96) 
2.06 53.8 156 O.383 12.1 1.4 
(3.2) 
3.90 49.8 244 O.941 29.7 1.4 
(7.8) 
PVP-PEOs concentration in mg/ml. 
Corrected optical density at 325 mm for pyrene-loaded PVP-PEO micelles. 
Note that the intrinsic solubility of pyrene yields an OD of ca. 0.02, so that 
a factor of ca. 50 solubilization improvement is obtained. This improvement 
should scale with the total micelle concentration. 
I/I ratio for pyrene. No excimer emission is observed. 
"Mass of pyrene in micrograms in 5.00 ml of the micelle solution. The values 
in parenthesis are the percent of the total available pyrene found in the 
micelle. 
Hydrodynamic diameter of micelle by QELS in nm. 
"Scattering intensity of micelles by QELS in Kcounts/sec. 
EXAMPLE 4 
Preparation of Micelles by Titration 
In general, the desired amount of P2VP-PEO (usually 5.0 
mg) was dissolved in 5.0 ml 0.1M HCl (resulting pH is ~1). 
Next, 0.1 M NaOH was added dropwise to a vigorously 
stirred solution as the pH is monitored. If a titration curve 
was to be generated, the base was added in 20 ul increments 
and the pH was recorded on the HP computer. As the 
titration approached the point at which micelles form (pH 
~4.0–4.9) for the more concentrated solutions, blue Swirls 
were observed in the Solution due to Scattering by micelles. 
This Scattering was allowed to dissipate as the Solution 
homogenized before the next quantity of base was added. 
The titration was stopped at the desired pH (ca. 7, 9 or 11). 
EXAMPLE 5 
Preparation and Loading of Micelles by Direct 
Dissolution 
The P2VP-PEOso copolymer was soluble directly in 
deionized water, regardless of its morphological State. 
Micelles formed spontaneously. A 5.0 mg quantity of P2VP 
PEOs was simply added to 5.0 ml of deionized water and 











(DPA, pyrene, etc.) was to be loaded into the micelle core, 
it was dissolved in benzene along with the desired ratio of 
polymer. The Solution was freeze-dried and the resulting 
Solid was redispersed in deionized water with a significant 
retention of the hydrophobic species. 
EXAMPLE 6 
Preparation of P2VP-PEO HCl Salt 
The HCl polymer salt i.e., P(2VP.HCl)-PEO, was pro 
duced by dissolving the neutral polymer in 1,4-dioxane and 
adding concentrated HCl (38%). The P(2VP.HCl)-PEO pre 
cipitated from dioxane into the water layer which was 
separated and freeze-dried. A 20 mg quantity of P2VP-PEO 
was precipitated from 15 ml 1,4-dioxane. The freeze-dried 
Sample dissolved molecularly (unimerically) in 16 ml of 
water with a resulting pH of 2.5. No scattering was observed 
in this solution. This was basified as above to produce 
micelles. 
EXAMPLE 7 
Loading of Hydrophobic Compound into Micelles: 
Simple Mixing 
A micelle containing Solution (at a pH above the pKa for 
the N-heterocycle nitrogen, about a pH of 5) is stirred in an 
aqueous Solution in the presence of the hydrophobic com 
pound. After equilibration, the micelles are separated from 
undissolved hydrophobic compound by conventional micro 
filtration (0.45 um pore size). This method generally works 
for hydrophobic compounds exhibiting Some degree of 
water solubility. 
EXAMPLE 8 
Loading of Hydrophobic Compound into Micelles: 
Biphasic System 
The hydrophobic compound is dissolved in high concen 
trations in a water immiscible organic Solvent. An aqueous 
solution containing PVP-PEO micelles contained in a dialy 
sis tube is place in contact with the organic Solvent. After 
equilibration, the dialysis tubing containing micelles is 
removed. 
EXAMPLE 9 
Loading of Hydrophobic Compound into Micelles: 
Cotitration 
An initially acidic aqueous solution containing PVP-PEO 
is mixed with a hydrophobic compound. The solution pH is 
raised by the addition of a base to at least about a pH of 5. 
Upon micelle formation, the hydrophobic compound is 
incorporated into the micelles which are separated from the 
Solution using conventional methods. 
EXAMPLE 10 
Loading of 9,10-Diphenylantracene (DPA) into 
Micelles: Direct Dissolution of Freeze Dried Solid 
A known quantity of DPA is dissolved in a known 
quantity of benzene. PVP-PEOs, at a loading of 5 mg/mL 
of Solution, is added to the benzene and the mixture Stirred. 
Following equilibration, the solution is freeze dried. The 
Solid is then Suspended in water, to a concentration of 1 mg 
Solids/mL of Solution, and filtered. Analysis reveals approxi 
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mately 24% of the DPA was loaded into the micelles. The 
micelles are stable with respect to aggregation and DPA 
loading. 
EXAMPLE 11 
Loading of Pyrene into Micelles: 
Direct Dissolution of Freeze Dried Solid 
The above procedure for DPA is followed for loading 
pyrene into the micelles. Analysis reveals approximately 
39% of the pyrene was loaded into the micelles. Emission 
Spectroscopy of the micelles shows a sharp increase in 
eXimer fluorescence of pyrene. 
EXAMPLE 12 
Methods for the Isolation of Micelles 
Freeze drying. A Solution containing micelles loaded with 
hydrophobic compound may be freeze dried. An aqueous 
suspension of PVP-PEO micelles in a flask is placed in a 
Sub-Zero degree Celsius bath until the solution solidifies. 
The solid is then subjected to high vacuum to remove all 
Solvents leaving the micelles in the flask. AS prepared, the 
micelles are very stable. 
Filtration. An aqueous Su Spension of 9, 1 
0-diphenylanthracene (DPA) containing P2VP-PEO 
micelles is passed through an 0.45 um filter which retains the 
DPA crystals and allows passage of the micelles. 
EXAMPLE 13 
General Method for the Preparation of Therapeutic 
Compound/Poly(vinyl N-heterocycle) 
Homopolymer/Poly(vinyl N-heterocycle) block-poly 
(alkvlene oxide) Combinations 
Selection of a particular poly(vinyl N-heterocycle)-block 
poly(alkylene oxide)/therapeutic compound combination is 
done by determining the relative solubility of the therapeutic 
compound in the respective poly(Vinly N-heterocycle) 
homopolymer. Thus, a thin film of the poly(vinyl 
N-heterocycle) is cast and placed in contact with a Solution 
containing the therapeutic compound. After equilibration, 
the film and Solution are Separated, and the film is dissolved 
in a Solvent which will also dissolve the therapeutic com 
pound. The solvent is then analyzed by GPC, and the relative 
mole fraction of therapeutic compound with respect to 
homopolymer is determined. A Suitable copolymer/ 
therapeutic compound combination will yield the desired 
mole fraction of therapeutic compound. 
EXAMPLE 1.4 
General Method for the Determination of 
Therapeutic Compound Release Rate 
Use of this method allows one to determine the relative 
Stability of a particular therapeutic compound/poly(Vinyl 
N-heterocycle)-block-poly (alkylene oxide) copolymer 
combination. A known amount of micelle containing powder 
is placed in dialysis tubing containing a first portion of an 
aqueous Solution. The tubing is then Sealed and placed in a 
Second portion of the Solvent. The amount of compound 
released into the Second portion is then monitored to develop 
a time course which reflects the release rate of compound 
from the micelle. 
EXAMPLE 1.5 
Preparation of A Therapeutic Compound/Poly 
(Vinvlpyridine)-block-poly(ethylene oxide)/Poly 
(vinylpyridine) Homopolymer Formulation 
A mildly acidic buffered Solution containing a known 











amount of poly(Vinlypyridine) homopolymer while stirring. 
A known amount of PVP-PEO copolymer is added until the 
desired ratioS of homopolymer:copolymer and therapeutic 
compound:copolymer are achieved. The pH of the Solution 
is then raised with base until micelle formation is complete. 
After equilibration, the micelles are separated from the 
solution by microfiltration and freeze dried. 
EXAMPLE 16 
Preparation of A Therapeutic Compound/Poly 
(vinylplridine)-block-poly(ethylene oxide)/Poly 
(vinylpyridine) Homopolymer Formulation for 
Injection 
A buffered Solution (pH <4) containing a known amount 
of losoxanthrone is mixed with a known amount of PVP 
homopolymer. A known amount of PVP-PEO copolymer is 
added until the weight ratio of homopolymer:copolymer is 
0.5:1 to 5:1 and the weight ratio of therapeutic compound 
:total polymer is 1:100 to 50:100. The pH is raised with 
dilute Sodium hydroxide until micelle formation is complete. 
After equilibration, the micelles and Supernatant are sepa 
rated by filtration and the micelles freeze dried. The micelle 
containing powder is placed in a vial containing NaHPO 
buffer and NaCl. The powder is then reconstituted with 
Saline or other Suitable liquid prior to injection. 
EXAMPLE 1.7 
Preparation of A Therapeutic Compound/Poly 
(vinylpyridine)-block-poly(ethylene oxide)/Poly 
(vinylpyridine) Homopolyrner Formulation for 
Tablet 
Sulindac containing freeze dried micellular powder 
(50-700 mg) is mixed with starch (10-200 mg) and lactose 
(10–200 mg). After granulation, magnesium Stearate (1-20 
mg) is added and the powders mixed and Screened. The 
mixture is then compressed into tablets weighing 75-1000 
mg each. The tablets are then coated with an enteric coating 
to minimize gastric dissolution and promote intestinal dis 
Solution. 
EXAMPLE 1.8 
Preparation of a Formulation for Hard Gelatin 
Capsules 
A daunorubicin containing freeze dried micellular powder 
(50-500 mg) is mixed with talc (1-100 mg) and lactose 
(1-200 mg). The powders are mixed and passed through a 
fine mesh screen. The powder is then filled into enteric 
coated hard gelatin capsules at a net fill of 60-800 mg per 
capsule. 
The above is a detailed description of particular embodi 
ments of the invention. It is recognized that departures from 
the disclosed embodiment may be made within the scope of 
the invention and that obvious modifications will occur to a 
person skilled in the art. The full scope of the invention is set 
out in the claims that follow and their equivalents. 
Accordingly, the claims and Specification should not be 
construed to unduly narrow the full Scope of protection to 
which the invention is entitled. 
What is claimed is: 
1. A micelle-containing formulation comprising: 
a pharmacologically active agent, and 
a poly (vinyl N-heterocycle)-block-poly (alkylene oxide) 
copolymer, wherein said vinyl N-heterocycle) is a 5 or 
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6 member ring and wherein Said copolymer is capable 
of forming micelles containing the pharmacologically 
active agent in an environment having a relatively 
higher pH than the copolymer. 
2. A formulation comprising pH-dependent block copoly 
mer micelles. 
3. The formulation of claim 2 wherein the block copoly 
mer is a poly (vinyl N-heterocycle)-block-poly (alkylene 
oxide) copolymer and when said Vinyl N-heterocycle is a 5 
or 6 member ring. 
4. The formulation of claim 2 wherein the pH-dependent 
block copolymer micelles further comprise a pharmacologi 
cally active agent. 
5. The formulation of claim 1 wherein the micelles are 
further defined as releasing the pharmacologically active 
agent in an aqueous environment having a relatively lower 
pH than the copolymer. 
6. The formulation of claim 5 wherein the relatively lower 
pH of the aqueous environment is further defined as a pH of 
between about 2 to a pH of about 6. 
7. A micelle containing pharmaceutical formulation com 
prising copolymers of formula I below: 
R-CHCH(R)-CHCH(R)O-H Formula I 
and isomeric, chiral, pharmaceutically acceptable Salt, 
oligomeric, polymeric, diastereomeric or racemic forms 
thereof, wherein: 
R is H or a polymerization initiator Selected from the 
group consisting of 
cumyl, S-butyl, n-butyl, 1,1-diphenylethyl, 1-phenyl-1- 
naphthylethyl, 1-phenyl-1-phenanthrylethyl, 
1-anthracyl-phenylethyl, 2-phenylpropyl and diphe 
nylmethyl; 
R is Selected from the group consisting of 
where, for the structures containing an R. Substituted 
nitrogen, R may be absent from the nitrogen and R 
may attach to the structure backbone by way of the 
nitrogen; 
R is H or C1-C5 alkyl; 
R is C1-C5 alkyl when R is attached to the copolymer 
backbone by an atom other than the nitrogen to which 
R is attached; 










m is independently Selected at each occurrence from 50 to 
500; and 
n is independently Selected at each occurrence from 50 to 
500. 
8. A micelle containing pharmaceutical formulation com 
prising homopolymers that include copolymers of the for 
mula II. 
R-CHCH(R)-H Formula II 
and isomeric, chiral, pharmaceutically acceptable Salt, 
oligomeric, polymeric, diastereomeric or racemic forms 
thereof, wherein: 
R is H or a polymerization initiator Selected from the 
group consisting of: 
cumyl, S-butyl, n-butyl, 1,1-diphenylethyl, 1-phenyl-1- 
naphthylethyl, 1-phenyl-1-phenanthrylethyl, 
1-anthracyl-1-phenylethyl and diphenylmethyl, 
R is selected from the group consisting of 
N NS NS 
-C i? R 5 5 5 2 4. Nes 
i. 
‘. S4 N 
Rs - 2 
N2N 2x1 
where, for the Structures containing an R. Substituted 
nitrogen, R may be absent from the nitrogen and R 
may attach to the structure backbone by way of the 
nitrogen; 
R is C1-C5 alkyl when R is attached to the copolymer 
backbone by an atom other than the nitrogen to which 
R is attached; 
Rs is H or C1-C5 alkyl attached to any carbon on R; and 
m is independently Selected at each occurrence from 50 to 
500; 
to provide a chemically stable compound. 
9. A micelle containing pharmaceutical drug delivery 
formulation comprising a pharmacologically active agent 
and micelles comprising the copolymers of claim 7, copoly 
mers of claim 8, or a combination thereof, wherein the 
pharmacologically active agent is released from the micelles 
in the presence of a decrease in pH. 
10. The micelle containing pharmaceutical drug delivery 
formulation of claim 1, wherein the pharmacologically 
active agent is an anti-cancer therapeutic agent. 
